Showing results (51-60 of 179) with videos related to

Sort By:
Pageof 18
Plos One|January 16, 2020
Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-studyFinlay A McAlister, Rajibul Mian, Jonas Oldgren, et al.
Journal of the American College of Cardiology|June 18, 2013
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillationJohn W Eikelboom, Stuart J Connolly, Robert G Hart, et al.
European Heart Journal|April 30, 2013
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summaryHein Heidbuchel, Peter Verhamme, Marco Alings, et al.
Journal of the American Heart Association|November 11, 2024
Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral AnticoagulationJulia Aulin, Karl Sjölin, Johan Lindbäck, et al.
Contemporary Clinical Trials Communications|July 1, 2024
Patients' experiences of clinical trial participation involving a product remotely assessing study drug adherenceCatrin Henriksson, Anneli Olsson, Kasper Andersen, et al.
American Heart Journal|August 4, 2024
Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stentDavid Erlinge, Jonas Andersson, Ole Fröbert, et al.
Circulation|January 5, 2012
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialStefan H Hohnloser, Jonas Oldgren, Sean Yang, et al.
Circulation|July 24, 2024
Neurofilament Light Chain and Risk of Stroke in Patients With Atrial FibrillationJulia Aulin, Karl Sjölin, Johan Lindbäck, et al.
European Heart Journal|June 11, 2016
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summaryHein Heidbuchel, Peter Verhamme, Marco Alings, et al.
Thrombosis and Haemostasis|January 29, 2016
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudyAgneta Siegbahn, Jonas Oldgren, Ulrika Andersson, et al.
Pageof 18